Innovent Biologics, Inc.: management transactions · Hong Kong · HKEX HKEX:innovent-biologics-inc HK HK · HKEX Mcap 139.3Bn€ Healthcare
Browse the full management transaction log of Innovent Biologics, Inc., a listed issuer based in Hong Kong. Shares are quoted on HK HK, under the supervision of HKEX. Operating in the Healthcare sector, Innovent Biologics, Inc. has logged 11 insider filings. Market capitalisation: €139.3bn. The latest transaction was reported on 13 May 2026 — Sale. Among the most active insiders: Ede Ronald Hao Xi. Every trade is openly available.
Financial data FY ended December 2025 · cache
Analyst consensus
27 analysts 82.90 € Target 116.42 €(+45%) 157.63 €
Income statement
Revenue 13.04 Bn€
Gross profit 11.29 Bn€ 87% margin
Net income 813.6 M€ 6.2% margin
Valuation
PER (trailing) 148.7x
PER (forward) 34.9x
P/Book 6.3x
Beta 0.24
Balance sheet & cash
Market cap 139.29 Bn€
Total debt 2.82 Bn€
Free Cash Flow 9.32 Bn€
Debt / Equity 15%
Profitability & ownership
ROE 5.0%
ROA 1.6%
% insiders 6.3%
% institutions 55.8%
Last declaration on 13 May 2026
Declarations 11 total
Executives ● Sale16 HKEX
€13m 1,352,952 shares @ €9.6873 0.0094% mcap 100.0% of flow
HKEX:DA20260512E00541 · 11 May 2026
Executives ● Purchase7 HKEX
24,226 shares
HKEX:DA20260402E00009 · 30 Mar 2026
Ideal exit: 25 Dec 2026 (T+270) Executives ● Purchase7 HKEX
24,226 shares
HKEX:DA20260402E00005 · 30 Mar 2026
Ideal exit: 25 Dec 2026 (T+270) Executives ● Purchase7 HKEX
225,000 shares
HKEX:DA20260402E00002 · 30 Mar 2026
Ideal exit: 25 Dec 2026 (T+270) Executives ● Sale12 HKEX
€9m 1,000,000 shares @ €9.4648 0.0068% mcap 50.5% of flow
HKEX:DA20260402E00001 · 30 Mar 2026
Executives ● Sale12 HKEX
€9m 986,000 shares @ €9.4138 0.0067% mcap 49.5% of flow
HKEX:DA20260401E00593 · 27 Mar 2026
Executives ● Purchase7 HKEX
24,226 shares
HKEX:DA20260402E00006 · 30 Mar 2026
Ideal exit: 25 Dec 2026 (T+270) Executives ● Purchase7 HKEX
24,226 shares
HKEX:DA20260402E00010 · 30 Mar 2026
Ideal exit: 25 Dec 2026 (T+270) Executives ● Purchase7 HKEX
1,863,000 shares
HKEX:DA20260402E00003 · 30 Mar 2026
Ideal exit: 25 Dec 2026 (T+270) Executives ● Purchase7 HKEX
330,000 shares
HKEX:DA20260402E00008 · 30 Mar 2026
Ideal exit: 25 Dec 2026 (T+270) Executives ● Purchase7 HKEX
39,366 shares
HKEX:DA20260402E00007 · 30 Mar 2026
Ideal exit: 25 Dec 2026 (T+270)